{
    "organizations": [],
    "uuid": "1a045260b04e3780f8f75463915b37627988d917",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/20/globe-newswire-depomed-to-report-fourth-quarter-fiscal-year-2017-financial-results-on-tuesday-february-27-2018.html",
    "ord_in_thread": 0,
    "title": "Depomed to Report Fourth Quarter Fiscal Year 2017 Financial Results on Tuesday, February 27, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "NEWARK, Calif., Depomed, Inc. (NASDAQ:DEPO) today announced that it will release fourth quarter fiscal year 2017 financial results on Tuesday, February 27, 2018, after the close of markets. The Company will host a conference call beginning at 4:30 p.m. EST (1:30 p.m. PST) to discuss its results.\nParticipants can access the live webcast from the Investor Relations section of Depomed's website at http://www.depomed.com . Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.\nAudio Conference Call:\nU.S. Dial-in Number: 1-844-839-0046 International Dial-in Number: 1-857-270-6032 Conference ID: 2157887 An archived webcast replay will be available on the Company's website for three months.\nAbout Depomed\nDepomed is a leading specialty pharmaceutical company committed to putting the Patient First in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain businesses and its emerging Specialty Business is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com .\nINVESTOR AND MEDIA CONTACTS:\nChristopher Keenan\nVP, Investor Relations and Corporate Communications\n510-744-8000\nckeenan@depomed.com\nDaniel Peisert\nVP, Business Development\ndpeisert@depomed.com\nSource:Depomed, Inc.",
    "published": "2018-02-21T00:05:00.000+02:00",
    "crawled": "2018-02-21T00:10:57.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "newark",
        "depomed",
        "nasdaq",
        "depo",
        "today",
        "announced",
        "release",
        "fourth",
        "quarter",
        "fiscal",
        "year",
        "financial",
        "result",
        "tuesday",
        "february",
        "close",
        "market",
        "company",
        "host",
        "conference",
        "call",
        "beginning",
        "est",
        "pst",
        "discus",
        "result",
        "participant",
        "access",
        "live",
        "webcast",
        "investor",
        "relation",
        "section",
        "depomed",
        "website",
        "http",
        "please",
        "access",
        "website",
        "minute",
        "prior",
        "start",
        "call",
        "download",
        "install",
        "necessary",
        "audio",
        "software",
        "archived",
        "webcast",
        "replay",
        "available",
        "company",
        "website",
        "three",
        "month",
        "audio",
        "conference",
        "call",
        "number",
        "international",
        "number",
        "conference",
        "id",
        "archived",
        "webcast",
        "replay",
        "available",
        "company",
        "website",
        "three",
        "month",
        "depomed",
        "depomed",
        "leading",
        "specialty",
        "pharmaceutical",
        "company",
        "committed",
        "putting",
        "patient",
        "first",
        "everything",
        "depomed",
        "focused",
        "enhancing",
        "life",
        "patient",
        "family",
        "physician",
        "provider",
        "payors",
        "commercialization",
        "product",
        "area",
        "pain",
        "neurology",
        "development",
        "drug",
        "area",
        "unmet",
        "medical",
        "need",
        "depomed",
        "currently",
        "market",
        "three",
        "medicine",
        "focused",
        "neuropathic",
        "pain",
        "migraine",
        "neurology",
        "pain",
        "business",
        "emerging",
        "specialty",
        "business",
        "focused",
        "orphan",
        "drug",
        "indication",
        "area",
        "unmet",
        "medical",
        "need",
        "learn",
        "depomed",
        "visit",
        "investor",
        "medium",
        "contact",
        "christopher",
        "keenan",
        "vp",
        "investor",
        "relation",
        "corporate",
        "communication",
        "ckeenan",
        "daniel",
        "peisert",
        "vp",
        "business",
        "development",
        "dpeisert",
        "source",
        "depomed",
        "inc"
    ]
}